Vergelijking

Glepaglutide vs. Histrelin

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

geen gegevens

220810-26-4

Molecuulmassa

geen gegevens

1323.52 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Histrelin

Continuous GnRH-agonist stimulation downregulates and desensitises the pituitary GnRH receptors — after the initial rise, LH, FSH and the sex hormones fall persistently.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Glepaglutide	Histrelin
Duitsland	Niet goedgekeurd	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Glepaglutide

Volledige vermelding →

Histrelin

Volledige vermelding →

Frequently asked questions

What is the difference between Glepaglutide and Histrelin?: Glepaglutide is classified as "Onderzoek (overig)", while Histrelin is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Histrelin?: The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Histrelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Histrelin in Germany and the United States?: Duitsland: Glepaglutide — Niet goedgekeurd, Histrelin — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Histrelin — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Histrelin

Duitsland

Niet goedgekeurd

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Glepaglutide and Histrelin?

Glepaglutide is classified as "Onderzoek (overig)", while Histrelin is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Histrelin: Histrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Histrelin?

The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane RCT" for Histrelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Histrelin in Germany and the United States?

Duitsland: Glepaglutide — Niet goedgekeurd, Histrelin — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Histrelin — Op recept. These are factual summaries with source and review date on the individual pages.